MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41391-023-00740-9

Медицинская библиотека · Prostate cancer and prostatic diseases · 2023

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.

Jones Robert Hugh, Fizazi Karim, James Nicholas D, Tammela Teuvo L, Matsubara Nobuaki, Priou Frank, Beuzeboc Philippe, Lesimple Thierry, Bono Petri, Kataja Vesa, Garcia Jorge A, Protheroe Andrew, Shore Neal, Aspegren John, Joensuu Heikki, Kuss Iris, Fiala-Buskies Sabine, Vjaters Egils

СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available.

METHODS

Treatment-emergent adverse events (TEAEs) for patients receiving darolutamide for a median of 38 months (n = 13) are described in this pooled analysis of individual patient data from phase 1/2 studies.

RESULTS

All patients reported TEAEs (mostly grade 1/2). The most common TEAEs were diarrhea, abdominal pain, and nausea. Serious TEAEs were reported in six patients (none related to darolutamide). All treatment-related TEAEs (n = 5) were grade 1.

CONCLUSIONS

Long-term darolutamide treatment was well tolerated; no new safety signals observed. In patients with mCRPC, long-term darolutamide treatment was well tolerated and no new safety signals were observed. These findings are consistent with previous reports, demonstrating a favorable safety and tolerability profile of darolutamide.

Для цитирования: Jones Robert Hugh, Fizazi Karim, James Nicholas D, Tammela Teuvo L, Matsubara Nobuaki, Priou Frank, Beuzeboc Philippe, Lesimple Thierry, Bono Petri, Kataja Vesa, Garcia Jorge A, Protheroe Andrew, Shore Neal, Aspegren John, Joensuu Heikki, Kuss Iris, Fiala-Buskies Sabine, Vjaters Egils. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.. Prostate cancer and prostatic diseases. 2023. DOI: 10.1038/s41391-023-00740-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.